Cannabis Science Inc. Issues First Market and Revenue Guidance in Regards to the Top 10 Cancer Formulations the Company Intends Focus on over Next Ten Years

Published: Dec 14, 2011

DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS.ob), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that we have a variety of cannabis-based formulations that target critical ailments worldwide. Illnesses ranging from cancer to pain management give the company a large market and revenue base potential. As outlined on the company website our initial target of self-administered cancer formulations proves to be the fastest to market application as prompted by recent successful cannabis-based treatments outlined in earlier press releases issued by the Company.

Back to news